肿瘤细胞治疗研究
英文原题：Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
我们的结果表明，与单靶点抗CD19和抗CD22 CAR-T相比，抗CD19/CD22 CAR-T的复发率和神经毒性发生率更低，但在完全缓解、微小残留病、总生存期和细胞因子释放综合征方面获得了相似的结果。
复发/难治性B细胞急性淋巴细胞白血病（R/R B-ALL）是一种具有挑战性的疾病，成人患者缓解率和生存率均较低。抗CD19CAR-T 细胞疗法已获批用于这些患者。近期开发了针对CD19和CD22的双靶点CAR-T，以提高单靶点疗法的疗效；然而，该双靶点疗法改善的程度尚未确定。我们进行了一项关于CAR-T疗效和安全性的meta分析，比较抗CD19、抗CD22与双靶点抗CD19/CD22 CAR-T，以阐明这些疗法在成人R/R B-ALL患者中的差异和局限性。尽管我们的研究存在源于纳入文献异质性的局限性，但我们的结果提示，与单靶点抗CD19和抗CD22 CAR-T相比，抗CD19/CD22 CAR-T的复发和神经毒性发生率更低，但在完全缓解、微小残留病、总生存和细胞因子释放综合征方面获得了相似的结果。
Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rates of remission and survival in adult patients. Anti-CD19 Chimeric Antigen Receptor T-cells (CAR-Ts) therapies have been approved for these patients. Dual-target CAR-Ts against CD19 and CD22 have recently been developed to improve the efficacy of the single-target therapy; however, extent of the improvement using this dual-target therapy has yet to be determined. We performed a meta-analysis of the outcome and safety of CAR-Ts, comparing anti-CD19 vs anti-CD22 vs dual-target anti-CD19/CD22 CAR-Ts, to elucidate the differences and limitations of these therapies in adult patients with R/R B-ALL. Although the limitations of our study derived from heterogeneity in the included publications, our results suggest that anti-CD19/CD22 CAR-Ts generate lower incidence of relapse and neurotoxicity, but similar results were obtained regarding complete remission, minimal residual disease, overall survival, and cytokine release syndrome compared with single-target anti-CD19 and anti-CD22 CAR-Ts.
MEMBER ACCOUNT
登录成功会直接打开下一页。
